sulfinpyrazone has been researched along with Coronary Disease in 106 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the relative importance of arachidonic acid pathway products on vulnerability to ventricular fibrillation (VF), we examined the effects of synthesis inhibitors and a receptor blocker acting in the cyclooxygenase (C) and lipoxygenase (L) pathways on VF thresholds in a feline model of coronary occlusion." | 7.67 | Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. ( Cooper, DR; Kelliher, GJ; Kowey, PR, 1988) |
| "In patients treated with sulfinpyrazone, an apparent reduction in the incidence of sudden death and presumed ventricular fibrillation has been reported." | 7.66 | Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. ( Escobinas, AJ; Jorgensen, OB; Moschos, CB; Regan, TJ, 1981) |
| " These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins." | 5.05 | Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "To determine the relative importance of arachidonic acid pathway products on vulnerability to ventricular fibrillation (VF), we examined the effects of synthesis inhibitors and a receptor blocker acting in the cyclooxygenase (C) and lipoxygenase (L) pathways on VF thresholds in a feline model of coronary occlusion." | 3.67 | Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. ( Cooper, DR; Kelliher, GJ; Kowey, PR, 1988) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| "In patients treated with sulfinpyrazone, an apparent reduction in the incidence of sudden death and presumed ventricular fibrillation has been reported." | 3.66 | Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. ( Escobinas, AJ; Jorgensen, OB; Moschos, CB; Regan, TJ, 1981) |
| "Treatment with sulfinpyrazone or aspirin/dipyridamole did not produce changes in platelet survival time or plasma beta TG concentration that were significantly different from the values during the placebo phase." | 2.65 | Platelet tests and antiplatelet drugs in coronary artery disease. ( Butt, R; de Boer, AC; Gent, M; Genton, E; Han, P; Turpie, AG, 1983) |
| "Dipyridamole can inhibit both platelet adhesion and aggregation by raising the platelet cyclic AMP level through phosphodiesterase inhibition." | 2.37 | Aspirin and other platelet-aggregation inhibiting drugs. ( Gallus, AS, 1985) |
| "In a sulfinpyrazone-treated group 3 out of 8, and in a metoprolol-treated group 2 out of 5 animals died." | 1.27 | Sudden death related to advanced coronary atherosclerosis in mini-pigs: influence of some drugs. ( Jacobsson, L; Lundholm, L; Wingren, G, 1984) |
| "Sulfinpyrazone was given intravenously as a bolus and by infusion to achieve two different and stable serum levels." | 1.27 | Dose-related cardiac electrophysiologic effects of sulfinpyrazone. ( Wyse, DG, 1985) |
| " Starting dosage was 200 mg per day; daily dosage was then increased every 4 days of 200 mg, or kept constant for another 4 days, according to each patient's renal function, up to 800 mg per day." | 1.27 | [Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]]. ( Bertolini, G; Borghi, C; Naliato, P, 1985) |
| "Coronary heart disease is the leading cause of death in the gouty and nongouty population." | 1.26 | Changing trends of mortality in gout. ( Talbott, JH; Yü, T, 1980) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 102 (96.23) | 18.7374 |
| 1990's | 3 (2.83) | 18.2507 |
| 2000's | 1 (0.94) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simon, JA | 1 |
| Boissel, JP | 1 |
| Leizorovicz, A | 1 |
| Faucomprez, C | 1 |
| McNicol, GP | 1 |
| Genton, E | 6 |
| Perrenoud, JJ | 1 |
| Marshall, AJ | 1 |
| Loew, D | 1 |
| Breddin, K | 1 |
| Uberla, K | 1 |
| Friedewald, WT | 1 |
| Schoenberger, JA | 1 |
| Spann, JF | 1 |
| Kelton, JG | 1 |
| Chodorowski, Z | 1 |
| Hughes, A | 1 |
| Daunt, S | 1 |
| Vass, G | 1 |
| Wickes, J | 1 |
| Webster, J | 1 |
| Cade, JF | 1 |
| Doyle, DJ | 1 |
| Chesterman, CN | 1 |
| Morgan, FJ | 1 |
| Rennie, GC | 1 |
| Sherry, S | 3 |
| de Boer, AC | 1 |
| Han, P | 1 |
| Turpie, AG | 5 |
| Butt, R | 1 |
| Gent, M | 3 |
| Mehta, J | 3 |
| Stamler, J | 1 |
| Eichner, ER | 1 |
| Ordinas, A | 1 |
| Gitler, B | 1 |
| Gitler, ES | 1 |
| Karmazyn, M | 1 |
| Jacobsson, L | 1 |
| Lundholm, L | 1 |
| Wingren, G | 1 |
| Bouchier-Hayes, D | 1 |
| Pagano, T | 1 |
| Nair, CK | 1 |
| Sketch, MH | 1 |
| Van Aken, WG | 1 |
| Polli, EE | 1 |
| Cortellaro, M | 1 |
| Mustard, JF | 2 |
| Packham, MA | 2 |
| Kinlough-Rathbone, RL | 2 |
| Selzer, A | 1 |
| Whisnant, JP | 1 |
| Verstraete, M | 5 |
| Weiss, HJ | 2 |
| O'Grady, J | 1 |
| Bunting, S | 1 |
| Moncada, S | 1 |
| Fuster, V | 4 |
| Chesebro, JH | 3 |
| Reimers, HJ | 1 |
| Misera, R | 1 |
| Schneider, W | 1 |
| Loogen, F | 1 |
| Sloan, RW | 1 |
| Cristol, R | 1 |
| Castaldi, PA | 1 |
| Mehta, JL | 1 |
| Hirsh, J | 7 |
| Verdecchia, P | 1 |
| Raeder, EA | 1 |
| Verrier, RL | 1 |
| Lown, B | 1 |
| Pstruzinová, H | 1 |
| Goderová, Z | 1 |
| Kristan, M | 1 |
| Russell, DC | 1 |
| Moschos, CB | 1 |
| Escobinas, AJ | 1 |
| Jorgensen, OB | 1 |
| Regan, TJ | 1 |
| Steele, P | 3 |
| Rainwater, J | 2 |
| Yü, T | 1 |
| Talbott, JH | 1 |
| Croveri, G | 1 |
| Hutchinson, RG | 1 |
| Haft, JI | 1 |
| Weston, MJ | 1 |
| Avellone, G | 1 |
| Mandalà, V | 1 |
| Novo, S | 1 |
| Davì, G | 1 |
| Pinto, A | 1 |
| Riolo, FP | 1 |
| Vogel, R | 1 |
| Didisheim, P | 2 |
| Prozan, GB | 1 |
| Dettori, AG | 1 |
| Pini, M | 1 |
| Quintavalla, R | 1 |
| Gantmacher, ML | 1 |
| Oelz, O | 1 |
| Mehta, P | 1 |
| Armitage, P | 1 |
| Harker, LA | 4 |
| Michaels, L | 1 |
| Galbraith, PA | 1 |
| Ledwich, JR | 1 |
| Battock, D | 1 |
| Stein, PD | 1 |
| Dalen, JE | 1 |
| Goldman, S | 1 |
| Schwartz, L | 1 |
| Théroux, P | 1 |
| Ferlito, S | 1 |
| Northover, BJ | 3 |
| Shalaev, SV | 1 |
| Bélanger, GL | 1 |
| Lavallée, JP | 1 |
| Lenis, J | 1 |
| Ouellet, CA | 1 |
| Borhani, NO | 1 |
| Tomov, I | 1 |
| Gelman, JS | 1 |
| Frishman, WH | 1 |
| Miller, KP | 1 |
| Puri, VK | 1 |
| Rawat, A | 1 |
| Sharma, A | 1 |
| Mehrotra, A | 1 |
| Hasan, M | 1 |
| Shanker, K | 1 |
| Verma, M | 1 |
| Sinha, JN | 1 |
| Bhargava, KP | 1 |
| Eller, BT | 1 |
| Lynch, JJ | 1 |
| Patterson, E | 1 |
| Lucchesi, BR | 1 |
| Cooper, DR | 1 |
| Kelliher, GJ | 1 |
| Kowey, PR | 1 |
| Steele, PM | 1 |
| Liusov, VA | 2 |
| Savenkov, MP | 1 |
| Bokarev, IN | 1 |
| Golikov, AP | 1 |
| Ptushkin, VV | 1 |
| Zvereva, TV | 1 |
| Resnekov, L | 1 |
| Chediak, J | 1 |
| Lewis, D | 1 |
| Brown, BG | 1 |
| Ekeström, S | 1 |
| Henderson, AH | 1 |
| Jewitt, DE | 1 |
| Oliver, MF | 1 |
| Sleight, P | 1 |
| Głab-Kordecka, E | 1 |
| Maekawa, T | 1 |
| Lecompte, T | 1 |
| Samama, M | 1 |
| Gallus, AS | 1 |
| Jouve, R | 1 |
| Larrue, J | 1 |
| Wyse, DG | 1 |
| Bertolini, G | 1 |
| Naliato, P | 1 |
| Borghi, C | 1 |
| Douglas, AS | 1 |
| Gormsen, J | 1 |
| Andersen, LA | 1 |
41 reviews available for sulfinpyrazone and Coronary Disease
| Article | Year |
|---|---|
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
Drug therapy of hypertension and ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Antihypertensive Agents; Aspirin; Clofibrate; C | 1981 |
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam | 1983 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
[Perspectives of the preventive treatment of patients after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Death, Sudden; Exercise Therapy; Humans; Myo | 1984 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
Efficacy of antiplatelet drugs in the maintenance of aortocoronary vein bypass graft patency.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Diseas | 1983 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
[Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
Topics: Anticoagulants; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Flurbiprof | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
Antithrombotic drugs in relation to prostaglandin metabolism.
Topics: Aspirin; Coronary Disease; Dipyridamole; Extracorporeal Circulation; Fibrinolytic Agents; Heparin; H | 1980 |
[Platelet antiaggregants and arteriopathies].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyr | 1981 |
Antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyridamole; Hea | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
[Platelets and prostaglandins in ischemic cardiopathy. Theoretical and practical aspects and research prospects].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Platelet Aggrega | 1982 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
Actions and clinical status of platelet-suppressive agents.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Heart Valve Dis | 1978 |
Platelet function inhibitors: their clinical use.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease | 1978 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
Antiplatelet drugs in thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Drug Therapy, Combination; | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
[Treatment with antiplatelet drugs. Current status of knowledge].
Topics: Aspirin; Blood Platelet Disorders; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dextrans | 1979 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts following percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Coronary Disease; Humans; In | 1992 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myoca | 1985 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
[Antiplatelet therapy of thrombosis].
Topics: Animals; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Postoperative Complications; | 1986 |
Aspirin and other platelet-aggregation inhibiting drugs.
Topics: Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Female; Heart Valv | 1985 |
Management of thrombotic diseases.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebrovascular Disorders; Coronary Dis | 1971 |
30 trials available for sulfinpyrazone and Coronary Disease
| Article | Year |
|---|---|
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone.
Topics: Angina Pectoris; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Coronary Artery By | 1982 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Platelet tests and antiplatelet drugs in coronary artery disease.
Topics: Adult; Aspirin; beta-Thromboglobulin; Blood Platelets; Cell Survival; Coronary Disease; Dipyridamole | 1983 |
Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dip | 1983 |
Pharmacological trials: primary and secondary prevention of coronary heart disease.
Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
Efficacy of antiplatelet drugs in the maintenance of aortocoronary vein bypass graft patency.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Diseas | 1983 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
The Canadian trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Canada; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts).
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1981 |
[Platelets and coronary artery disease (CAD) (author's transl)].
Topics: Animals; Aspirin; Autopsy; Blood Platelets; Cardiomyopathies; Cell Wall; Clinical Trials as Topic; C | 1980 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
Drug therapy: antiplatelet therapy (second of two parts).
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical T | 1978 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Proceedings: A clinical trial of antiplatelet therapy in patients with coronary arterial disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Humans; Sulfinpyrazone | 1975 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease.
Topics: Adult; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Female; Hum | 1986 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary A | 1986 |
[Secondary prevention of ischemic heart disease. Evaluation of platelet function in patients treated with anticoagulants and cod liver oil].
Topics: Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Cod Liver Oil; Coronary Disease; Dip | 1986 |
A critical appraisal of the clinical efficiency of anti-platelet drugs.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1986 |
[Eicosanoids, myocardial ischemia and sudden death].
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Coronary Disease; Cyclooxygenase I | 1985 |
49 other studies available for sulfinpyrazone and Coronary Disease
| Article | Year |
|---|---|
Clinical trials of uric acid lowering for coronary heart disease risk reduction.
Topics: Clinical Trials as Topic; Coronary Disease; Humans; Hyperuricemia; Myocardial Infarction; Platelet A | 2006 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
[Role of medical treatment in the rehabilitation of the coronary patient].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Heart Diseases; Humans; Myoc | 1981 |
[Inhibitors of thrombocytic function for prophylaxis of coronary heart disease (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Coronary Diseas | 1982 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
In vivo platelet activation following myocardial infarction and acute coronary ischaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Beta-Globulins; beta-Thromboglobulin; Blood Coagulation Diso | 1982 |
Antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dextrans; Dipyridamole; Epopr | 1983 |
A direct protective effect of sulphinpyrazone on ischaemic and reperfused rat hearts.
Topics: Animals; Blood Pressure; Coronary Disease; Creatine Kinase; Heart; In Vitro Techniques; Male; Myocar | 1984 |
Sudden death related to advanced coronary atherosclerosis in mini-pigs: influence of some drugs.
Topics: Animals; Cholesterol; Coronary Circulation; Coronary Disease; Coronary Vessels; Creatine Kinase; Dea | 1984 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |
Use of common antiplatelet drugs for vascular diseases.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Artery Bypass; Coronary Disease; Couma | 1983 |
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans | 1982 |
[The Anturan reinfarct study].
Topics: Aged; Coronary Disease; Death, Sudden; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 1980 |
Non-steroidal anti-inflammatory agents and coronary heart disease.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Caroti | 1980 |
On the limitation of therapeutic intervention trials in ischemic heart disease: a clinician's viewpoint.
Topics: Angina Pectoris; Anticoagulants; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; | 1982 |
Antiplatelet therapy.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprost | 1981 |
Platelets and coronary heart disease: therapy update.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Hemostasis | 1982 |
Effects of sulfinpyrazone on ventricular vulnerability in the normal and the ischemic heart.
Topics: Animals; Coronary Disease; Dogs; Female; Heart; Heart Conduction System; Lidocaine; Male; Myocardial | 1982 |
[A contribution to the study of blood platelet aggregation].
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation; Sulfinpyrazone | 1982 |
Haemodynamic effects of sulphinpyrazone in experimental myocardial ischaemia.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Dogs; Heart Rate; Hemodynamics; Sulfinpyrazone; V | 1981 |
Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia.
Topics: Acute Disease; Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Disease; Dogs; Electro | 1981 |
Relationship of plasma anti-heparin activity and platelet survival time in coronary disease.
Topics: Aspirin; Blood Coagulation Factors; Blood Platelets; Cell Survival; Coronary Disease; Dipyridamole; | 1980 |
Changing trends of mortality in gout.
Topics: Aged; Arteriosclerosis; Coronary Disease; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; | 1980 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
Sulfinpyrazone alone?
Topics: Coronary Disease; Humans; Sulfinpyrazone | 1981 |
Sulphinpyrazone after myocardial infarction.
Topics: Animals; Coronary Disease; Humans; Myocardial Infarction; Rabbits; Sulfinpyrazone | 1978 |
[Evaluation of antithrombin III activity in ischemic cardiopathy: changes due to treatment with platelet anti-aggregants].
Topics: Anticoagulants; Antithrombin III; Aspirin; Coronary Disease; Female; Humans; Male; Platelet Aggregat | 1979 |
Platelet-suppressant therapy in patients with coronary artery disease.
Topics: Adult; Blood Platelets; Cell Survival; Clofibrate; Coronary Artery Bypass; Coronary Disease; Death, | 1978 |
More on coronary bypass surgery--III.
Topics: Coronary Artery Bypass; Coronary Disease; Humans; Propranolol; Prospective Studies; Sulfinpyrazone; | 1979 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
Status of antiplatelet drugs in coronary heart disease.
Topics: Aspirin; Blood Platelets; Clofibrate; Coronary Disease; Dipyridamole; Humans; Male; Models, Biologic | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Are agents affecting platelet function clinically useful in patients with coronary artery disease?
Topics: Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clofibrate; Coro | 1976 |
Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.
Topics: Adult; Blood Platelets; Cell Survival; Cholesterol; Clofibrate; Coronary Disease; Humans; Hyperlipid | 1975 |
Continuous fluorimetric assessment of the changes in cytoplasmic calcium concentration during exposure of rat isolated myocardium to conditions of simulated ischaemia.
Topics: Animals; Calcium; Coronary Disease; Cytoplasm; Electric Stimulation; Flufenamic Acid; Fluorescent Dy | 1990 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
[Antiaggregants of thrombocytes in ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Humans; M | 1985 |
Electrophysiologic and antiarrhythmic actions of sulphinpyrazone and its sulfide metabolite G25671.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Cyclooxygenase Inhibitors; Dogs; Electrophysiolog | 1987 |
Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents, Non | 1988 |
Platelet-inhibitor therapy in cardiovascular disease. Effective defense against thromboembolism.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Bioprosthesis; Blood Platelets; Coronary Disease; Dip | 1985 |
[Anti-aggregation therapy of patients with ischemic heart disease].
Topics: Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Platelet Aggregation; Platelet Agg | 1988 |
[Use of anturan in patients with ischemic heart disease with a history of acute myocardial infarction].
Topics: Coronary Disease; Coronary Thrombosis; Humans; Male; Myocardial Infarction; Platelet Aggregation; Pl | 1987 |
A protective effect of sulphinpyrazone against coronary occlusion-induced shortening of myocardial refractory periods in the rat.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography; Heart | 1986 |
Electrical changes produced by injury to the rat myocardium in vitro and the protective effects of certain antiarrhythmic drugs.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Coronary Disease; Electric Stimulation; Heart Conduction S | 1987 |
Dose-related cardiac electrophysiologic effects of sulfinpyrazone.
Topics: Adult; Aged; Coronary Disease; Dose-Response Relationship, Drug; Electrophysiology; Female; Heart; H | 1985 |
[Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]].
Topics: Aged; Cerebrovascular Disorders; Coronary Disease; Creatinine; Dose-Response Relationship, Drug; Dru | 1985 |
[Incidence of thrombosis and the status of coagulation in ischaemic heart disease].
Topics: Acute Disease; Aspirin; Blood Coagulation; Chronic Disease; Coronary Disease; Depression, Chemical; | 1974 |